Arcus Biosciences (RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers (BMY)
Newsquawk Staff ·
Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical trial. This trial evaluates pumitamig (BNT327/BMS986545), an investigational PD-L1/VEGF-A bispecific antibody, being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other potential treatment options in advanced renal cell carcinoma (RCC).
Sources
- Amazon Web Services (AMZN) says its threat intelligence team detected exploitation of the PHP2Shell vulnerability before public disclosure
- [EARNINGS CALL] Tesla (TSLA) CEO Elon Musk says the company will increase production to meet demand; company is aiming to produce approximately 5mln vehicles annually by 2030
- [EARNINGS CALL] Meta (META) expects new AI businesses to generate incremental revenue from 2027 through subscriptions, transactions, advertising and enterprise offerings, with meaningful growth potential over time
- [EARNINGS CALL] IBM (IBM) says Q3 revenue growth accelerated to 6%, above the base case outlined in July, with acceleration across segments, while management expressed confidence in its balance-of-year outlook, supported by strong profitability and FCF
- Merck (MRK GY) is collaborating with Nvidia (NVDA), Microsoft (MSFT) and Dawn Health to develop novel support model for people living with rare tumours
Related headlines
- [EARNINGS CALL] Lam Research (LRCX) says its preliminary CY27 wafer fabrication equipment outlook exceeds USD 200bln (exp. CY26 USD 150bln), driven by DRAM, NAND and foundry/logic demand2 hours ago
- [EARNINGS CALL] Meta (META) CFO expects compute efficiency to improve tenfold over the next year2 hours ago
- [EARNINGS CALL] Meta (META) outlook; Revenue Guidance 73bln-76bln, FY 2026 Total Expenses Guidance 175bln-179bln, FY 2026 Capex Guidance 135bln-145bln (prev. 130bln-145bln)2 hours ago
- [EARNINGS CALL] Meta (META) CEO says Co. expects to grow Muse to serve billions of people, adding that more than 10mln people in the US and Canada have set up Muse personal agents in just a month and a half2 hours ago
- Kinder Morgan Inc (KMI) Q3 2026 (USD): Adj. EPS 0.35 (exp. 0.32), Revenue 4.531bln (exp. 4.38bln)2 hours ago
- Meta (META) CEO Zuckerberg weighs relocating from California if Prop 40 is enacted, Bloomberg reports3 hours ago
- International Business Machines (IBM) EPS 16.8bln (exp. 2.86), Revenue 17.1bln (exp. 16.81bln); reaffirms FY revenue guidance; Raises outlook for full-year free cash flow3 hours ago
- Lam Research (LRCX) Q1 2027 (USD): Adj. EPS 2.20 (exp. 2.18), Revenue 8.22bln (exp. 8.13bln), 3 hours ago
- Meta Platforms Inc (META) Q3 2026 (USD): EPS 3.83 (exp. 6.67), Revenue 64.6bln (exp. 63.31bln)3 hours ago
- EQT said to near deal for Qiagen at EUR 46.50/shr, Bloomberg reports3 hours ago
- Walmart (WMT) introduces agent profiles and agent gateway for AI-enabled shopping, to launch in customer accounts next month3 hours ago
- Meta (META) plans to introduce new nonvoting stock to fund its AI investments without diluting CEO Zuckerberg's control, reports Semafor citing sources; could be announced as soon as today alongside earnings4 hours ago
- Meta (META) must pay USD 25bln in penalties, a New Mexico judge ruled after jury found company misled consumers about privacy6 hours ago
- Senators express ‘grave concerns,’ launch inquiry into Google’s (GOOGL) AI push in schools, WSJ reports6 hours ago
- Newsquawk Daily US Earnings Estimates - 22nd October 2026: BX, LMT, VLO, PG, UNP, WDC, NEM, SPOT7 hours ago